LET'S TALK. 877-341-5968

No employee WANTS to have surgery. As the fiduciary of your company health plan, you owe it to your employees to offer them effective non-invasive options to treat the hundreds of orthopedic conditions you currently prescribe to only surgery. This is not a radical, experimental treatment…this is a Regenexx treatment. Regenexx procedures are FDA compliant, Randomized Control Trial proven procedures that can intervene on 70% of the surgeries you currently cover to treat common orthopedic conditions. If you have not included Regenexx as part of your healthcare plan, you are providing an archaic product to your most valuable asset that has been proven in RCT’s to be ineffective in over 50% of cases…that’s a huge risk and expense to incur.

“Am I appreciative? You have no idea how appreciative I am. I personally will be thanking Steve Lacy, CEO of Meredith. I am beyond grateful….I’d recommend doing it sooner than later. Had I known about this procedure years ago my life would be different now. ” – Meredith Employee 2017

Tim O’Neil, Director of Employee Benefits at Meredith Corporation, discusses why they added the Regenexx procedures to their self-funded plan.

In just over 2 years, we have reduced our corporate partners’ orthopedic surgical costs by up to 70%* at an overall savings of over $6 MILLION dollars.

Promoting Your Employee’s Well-being through the Nation’s Leader in Regenerative Medicine

Articles From Regenexx®

Incorporating the Regenexx procedures into your healthcare plan is a solid business decision based on the success of our partners and the success of our patients. The vast majority of employees treated by Regenexx have avoided the need for further surgery.

* This data was calculated based on the gross savings realized from substituting percutaneous orthobiologic procedures for invasive, elective orthopedic surgeries within our pilot program in Des Moines, IA. Now that we have more data from more clients, we will update our cost savings on a quarterly basis using a sampling methodology, later this year we will be introducing an actuarial based process.